InvestorsObserver is giving Urogen Pharma Ltd (URGN) an Analyst Rating Rank of 59, meaning URGN is ranked higher by analysts than 59% of stocks. The average price target for URGN is $31 and analyst’s rate the stock as a Strong Buy.
Wall Street analysts are rating URGN a Strong Buy today. Find out what this means to you and get the rest of the rankings on URGN!
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.
What's Happening With Urogen Pharma Ltd Stock Today?
Urogen Pharma Ltd (URGN) stock has gained 4.89% while the S&P 500 is down -1.16% as of 11:22 AM on Friday, Apr 22. URGN has risen $0.35 from the previous closing price of $7.06 on volume of 84,745 shares. Over the past year the S&P 500 has gained 5.03% while URGN is down -62.19%. URGN lost -$4.96 per share the over the last 12 months.
Click Here to get the full Stock Report for Urogen Pharma Ltd stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
